A. Bhadhuri, R. Insinga, P. Guggisberg, C. Panje, and M. Schwenkglenks, “Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland”, Swiss Med Wkly, vol. 149, no. 5152, p. w20170, Dec. 2019.